Document text
Principal Investigator: Leah Katzelnick
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $48,547
Funding agency: National Institute of Allergy and Infectious Diseases
We are collaborating with leaders of existing longitudinal cohort studies to: 1) Measure how preexisting immunity to endemic human coronaviruses and older SARS-CoV-2 variants modifies future risk of SARS-CoV-2 infection and COVID-19 disease in pediatric and adult populations, and 2) Prospectively track antigenic variation among SARS-CoV-2 variants.
Immunity to endemic coronaviruses and SARS-CoV-2 before and during the COVID-19 pandemic in children in Cebu, Philippines
Despite the implementation of control measures, the Philippines continues to have substantial community transmission of SARS-CoV-2. As of July 20, 2021, there have been 1.5 million COVID-19 cases in the Philippines, resulting in 26,844 deaths. The Philippine Food and Drug Administration has issued Emergency Use Authorization to eight COVID-19 vaccines. Mass COVID-19 vaccination officially began in the Philippines on March 1, 2021. As of July 19, 2021, only 9.6% of the Filipino population has received at least one dose of a COVID-19 vaccine. NIAID and University of the Philippines Manila are collaborating to study SARS-CoV-2 seroprevalence and COVID-19 incidence in children in the Central Visayas Region in the Philippines, a region where numerous variants of concern now circulate but where little is known about the infection and disease risk for SARS-CoV-2. This study is part of an ongoing longitudinal cohort of children 12-17 years of age and residing in Bogo and Balamban participating in the study entitled "Effect of baseline dengue serostatus among tetravalent dengue vaccine CYD-TDV (Dengvaxia) recipients on subsequent virologically confirmed dengue in the Philippines". This cohort provides a unique opportunity to interrogate immunity induced by endemic coronaviruses prior to the start of the COVID-19 pandemic (late 2019/early 2020) and follow the same children over the course of the pandemic (2020 and 2021). We are using ELISAs and epidemiological methods to measure serum antibodies to the spike antigens of SARS-CoV-2, OC43, HKU1, 229E, and NL63. In July 2021, prospective RT-PCR testing for COVID-19 among febrile cases in the cohort was initiated. Stored and prospectively collected serum samples will be tested for endemic coronavirus and SARS-CoV-2 antibodies.
Terms: <0-11 years old><17 year old><17 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><Adult><Adult Human><Antibodies><Antigen Variation><Antigenic Variability><Antigenic Variation><Blood Serum><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 antibody><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 testing><COVID-19 transmission><COVID-19 vaccination><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 testing><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><CoV-2><CoV2><Communities><Coronaviridae><Coronavirus><DENV vaccine><Death><Dengue><Dengue Vaccine><Dengue virus vaccine><Dengvaxia><Disease><Disorder><Dose><ELISA><Enzyme-Linked Immunosorbent Assay><Epidemiologic Methods><Epidemiological Methods><Epidemiological Techniques><Epidemiology><Evolution><FDA EUA><FDA Emergency Use Authorization><Fever><Filipino><Flavivirus><Food and Drug Administration><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Future><Group B Arbovirus><HCoV><Immune><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunology><Incidence><Long-term cohort><Long-term cohort study><Longitudinal cohort><Longitudinal cohort study><Longterm cohort><Longterm cohort study><Measures><Methods Epidemiology><NIAID><National Institute of Allergy and Infectious Disease><Philipines><Philippines><Phillipines><Phillippines><Population><Predisposition><Pyrexia><RT-PCR><RTPCR><Reverse Transcriptase Polymerase Chain Reaction><Risk><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 testing><SARS-CoV-2 transmission><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Seroprevalences><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Susceptibility><Testing><USFDA><United States Food and Drug Administration><Universities><Viral Diseases><Viral Epidemiology><Virus Diseases><Wuhan coronavirus><adulthood><age 17 years><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><cohort><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 testing><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><disease risk><disorder risk><emergency use authorization><epidemiologic><epidemiological><febrile><febris><hCoV19><human CoV><human corona virus><human coronavirus><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection risk><interdisciplinary approach><multidisciplinary approach><nCoV2><pandemic><pandemic disease><pediatric><prospective><reverse transcriptase PCR><seventeen year old><seventeen years of age><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 testing><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><variants of concern><viral infection><virology><virus infection><virus-induced disease><youngster>